|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pufall MA: Glucocorticoids and cancer. Adv
Exp Med Biol. 872:315–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu L, Aleksandrowicz E, Schönsiegel F,
Gröner D, Bauer N, Nwaeburu CC, Zhao Z, Gladkich J, Hoppe-Tichy T,
Yefenof E, et al: Dexamethasone mediates pancreatic cancer
progression by glucocorticoid receptor, TGFβ and JNK/AP-1. Cell
Death Dis. 8:e30642017. View Article : Google Scholar
|
|
5
|
Herr I and Pfitzenmaier J: Glucocorticoid
use in prostate cancer and other solid tumours: Implications for
effectiveness of cytotoxic treatment and metastases. Lancet Oncol.
7:425–430. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Volden PA and Conzen SD: The influence of
glucocorticoid signaling on tumor progression. Brain Behav Immun.
30(Suppl): S26–S31. 2013. View Article : Google Scholar
|
|
7
|
Herr I, Ucur E, Herzer K, Okouoyo S,
Ridder R, Krammer PH, von Knebel Doeberitz M and Debatin KM:
Glucocorticoid cotreatment induces apoptosis resistance toward
cancer therapy in carcinomas. Cancer Res. 63:3112–3120.
2003.PubMed/NCBI
|
|
8
|
Puhr M, Hoefer J, Eigentler A, Ploner C,
Handle F, Schaefer G, Kroon J, Leo A, Heidegger I, Eder I, et al:
The glucocorticoid receptor is a key player for prostate cancer
cell survival and a target for improved antiandrogen Therapy. Clin
Cancer Res. 24:927–938. 2018. View Article : Google Scholar
|
|
9
|
Iversen HG and Hjort GH: The influence of
corticoid steroids on the frequency of spleen metastases in
patients with breast cancer. Acta Pathol Microbiol Scand.
44:205–212. 1958. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sherlock P and Hartmann WH: Adrenal
steroids and the pattern of metastases of breast cancer. JAMA.
181:313–317. 1962. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melhem A, Yamada SD, Fleming GF, Delgado
B, Brickley DR, Wu W, Kocherginsky M and Conzen SD: Administration
of glucocorticoids to ovarian cancer patients is associated with
expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in
ovarian tissues. Clin Cancer Res. 15:3196–3204. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan D, Kocherginsky M and Conzen SD:
Activation of the gluco-corticoid receptor is associated with poor
prognosis in estrogen receptor-negative breast cancer. Cancer Res.
71:6360–6370. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong ET, Lok E, Gautam S and Swanson KD:
Dexamethasone exerts profound immunologic interference on treatment
efficacy for recurrent glioblastoma. Br J Cancer. 113:16422015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hirai H, Tomioka H, Mochizuki Y, Oikawa Y,
Tsushima F and Harada H: Clinical course of oral squamous cell
carcinoma in patients on immunosuppressant and glucocorticoid
therapy. J Oral Maxillofac Surg. 75:1980–1986. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang HY, Chang YL, Cheng CC, Chao MW, Lin
SI, Pan SL, Hsu CC, Liu TW, Cheng HC, Tseng CP, et al:
Glucocorticoids may compromise the effect of gefitinib in non-small
cell lung cancer. Oncotarget. 7:85917–85928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sørensen HT, Mellemkjaer L, Nielsen GL,
Baron JA, Olsen JH and Karagas MR: Skin cancers and non-hodgkin
lymphoma among users of systemic glucocorticoids: A
population-based cohort study. J Natl Cancer Inst. 96:709–711.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dietrich K, Schned A, Fortuny J, Heaney J,
Marsit C, Kelsey KT and Karagas MR: Glucocorticoid therapy and risk
of bladder cancer. Br J Cancer. 101:1316–1320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu M, Xu Z, Wang K, Wang N and Li Y:
microRNA and gene networks in human pancreatic cancer. Oncol Lett.
6:1133–1139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi M, Du L, Liu D, Qian L, Hu M, Yu M,
Yang Z, Zhao M, Chen C, Guo L, et al: Glucocorticoid regulation of
a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy
resistance of cervical cancer cells. J Pathol. 228:148–157. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heller A, Angelova AL, Bauer S, Grekova
SP, Aprahamian M, Rommelaere J, Volkmar M, Janssen JW, Bauer N,
Herr I, et al: Establishment and characterization of a novel cell
line, ASAN- PaCa, derived from human adenocarcinoma arising in
intraductal papillary mucinous neoplasm of the pancreas. Pancreas.
45:1452–1460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang S, Hao J, Xie F, Hu X, Liu C, Tong
J, Zhou J, Wu J and Shao C: Downregulation of miR-132 by promoter
methylation contributes to pancreatic cancer development.
Carcinogenesis. 32:1183–1189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar :
|
|
25
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,
et al: Combinatorial microRNA target predictions. Nat Genet.
37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kallifatidis G, Rausch V, Baumann B, Apel
A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G,
et al: Sulforaphane targets pancreatic tumour-initiating cells by
NF-kappaB-induced antiapoptotic signalling. Gut. 58:949–963. 2009.
View Article : Google Scholar
|
|
31
|
Zhang Y, Liu L, Fan P, Bauer N, Gladkich
J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, et al:
Aspirin counteracts cancer stem cell features, desmoplasia and
gemcitabine resistance in pancreatic cancer. Oncotarget.
6:9999–10015. 2015.PubMed/NCBI
|
|
32
|
Jørgensen S, Baker A, Møller S and Nielsen
BS: Robust one-day in situ hybridization protocol for detection of
microRNAs in paraffin samples using LNA probes. Methods.
52:375–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Amponsah PS, Fan P, Bauer N, Zhao Z,
Gladkich J, Fellenberg J and Herr I: microRNA-210 overexpression
inhibits tumor growth and potentially reverses gemcitabine
resistance in pancreatic cancer. Cancer Lett. 388:107–117. 2017.
View Article : Google Scholar
|
|
34
|
Fan P, Zhang Y, Liu L, Zhao Z, Yin Y, Xiao
X, Bauer N, Gladkich J, Mattern J, Gao C, et al: Continuous
exposure of pancreatic cancer cells to dietary bioactive agents
does not induce drug resistance unlike chemotherapy. Cell Death
Dis. 7:e22462016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z,
Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the
miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance
in multiple myeloma. Cancer Res. 75:4384–4397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim J, Jeong D, Nam J, Aung TN, Gim JA,
Park KU and Kim SW: MicroRNA-124 regulates glucocorticoid
sensitivity by targeting phosphodiesterase 4B in diffuse large B
cell lymphoma. Gene. 558:173–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Butz H, Rácz K, Hunyady L and Patócs A:
Crosstalk between TGF-β signaling and the microRNA machinery.
Trends Pharmacol Sci. 33:382–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zaravinos A: The Regulatory Role of
MicroRNAs in EMT and Cancer. J Oncol. 2015.865816:2015.
|
|
39
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Painter RC, Roseboom TJ and de Rooij SR:
Long-term effects of prenatal stress and glucocorticoid exposure.
Birth Defects Res C Embryo Today. 96:315–324. 2012. View Article : Google Scholar
|
|
41
|
Tang L, Shen H, Li X, Li Z, Liu Z, Xu J,
Ma S, Zhao X, Bai X, Li M, et al: MiR-125a-5p decreases after long
non-coding RNA HOTAIR knockdown to promote cancer cell apoptosis by
releasing caspase 2. Cell Death Dis. 7:e21372016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hong L, Han Y, Zhang H, Zhao Q and Qiao Y:
miR-210: A therapeutic target in cancer. Expert Opin Ther Targets.
17:21–28. 2013. View Article : Google Scholar
|
|
43
|
Chen QG, Zhou W, Han T, Du SQ, Li ZH,
Zhang Z, Shan GY and Kong CZ: MiR-378 suppresses prostate cancer
cell growth through downregulation of MAPK1 in vitro and in vivo.
Tumour Biol. 37:2095–2103. 2016. View Article : Google Scholar
|
|
44
|
Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu
F, Fan Y, Lang R, Fu L, Gu L, et al: MicroRNA-132 is frequently
downregulated in ductal carcinoma in situ (DCIS) of breast and acts
as a tumor suppressor by inhibiting cell proliferation. Pathol Res
Pract. 209:179–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL and Dahiya R: Genistein downregulates
onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation
and histone modification in prostate cancer cells. Br J Cancer.
110:1645–1654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Formosa A, Lena AM, Markert EK, Cortelli
S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P,
Finazzi-Agrò E, et al: DNA methylation silences miR-132 in prostate
cancer. Oncogene. 32:127–134. 2013. View Article : Google Scholar
|
|
47
|
Fu W, Tao T, Qi M, Wang L, Hu J, Li X,
Xing N, Du R and Han B: MicroRNA-132/212 upregulation inhibits
TGF-β-mediated epithelial-mesenchymal transition of prostate cancer
cells by targeting SOX4. Prostate. 76:1560–1570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kawashima H, Numakawa T, Kumamaru E,
Adachi N, Mizuno H, Ninomiya M, Kunugi H and Hashido K:
Glucocorticoid attenuates brain-derived neurotrophic
factor-dependent upregulation of glutamate receptors via the
suppression of microRNA-132 expression. Neuroscience.
165:1301–1311. 2010. View Article : Google Scholar
|
|
50
|
Zheng YB, Luo HP, Shi Q, Hao ZN, Ding Y,
Wang QS, Li SB, Xiao GC and Tong SL: miR-132 inhibits colorectal
cancer invasion and metastasis via directly targeting ZEB2. World J
Gastroenterol. 20:6515–6522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Smith LK, Shah RR and Cidlowski JA:
Glucocorticoids modulate microRNA expression and processing during
lymphocyte apoptosis. J Biol Chem. 285:36698–36708. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qin J, Ke J, Xu J, Wang F, Zhou Y, Jiang Y
and Wang Z: Downregulation of microRNA-132 by DNA hypermethylation
is associated with cell invasion in colorectal cancer. Onco Targets
Ther. 8:3639–3648. 2015.PubMed/NCBI
|
